Avancerad sökning

Visar resultat 11 - 15 av 45 avhandlingar som matchar ovanstående sökkriterier.

1. 11. Consequences of CYP2D6 polymorphism for the disposition and dynamics of tolterodine : a novel drug in the treatment of urinary bladder overactivity

   Författare :Niclas Brynne; Karolinska Institutet; Karolinska Institutet; []
   Nyckelord :active metabolite; CYP2D6; CYP3A4; disposition; drug interaction; fluoxetine; ketoconazole; metabolic ratio; pharmacokinetics; tolterodine;

   Sammanfattning : The pharmacokinetics and pharmacological effects of tolterodine were studied in man following administration of increasing oral and intravenous single-doses. The influence of metabolic phenotype in extensive and poor metabolizers of debrisoquine was determined. LÄS MER

3. 12. Characteristics of cytochrome P450-catalysed drug metabolism with focus on a black Tanzanian population

   Författare :Agneta Wennerholm; Karolinska Institutet; Karolinska Institutet; []
   Nyckelord :Drug metabolism; cytochrome P450; polymorphism; pharmacogenetics; genotyping; phenotyping; CYP2D6; CYP3A; debrisoquine; amodiaquine; alprazolam;

   Sammanfattning : The cytochrome P450 (CYP) enzymes display interindividual and interethnic variability that may alter the disposition of substances metabolised by these enzymes. Both genetic and environmental factors such as concomitant drug use and concurrent diseases influence the activities of these enzymes. LÄS MER

4. 13. Genetic polymorphism of xenobiotic metabolising enzymes : implications for interindividual and interethnic differences in drug metabolism and cancer susceptibility

   Författare :Irene Persson; Karolinska Institutet; Karolinska Institutet; []
   Nyckelord :Lung cancer; drug metabolism; genetic polymorphism; cytochrome P450; CYPIAI; CYP2EI; CYP2D6; interethnic differences.;

   Sammanfattning : Genetic factors are of importance for interindividual and interethnic differences in drug response and cancer susceptibility. In the present investigation the role of genetic polymorphism in the cytochromes P450 CYPIAI, CYP2C19, CYP2D6, CYP2EI as well as in glutathione S-transferase Ml (GSTMI) and microsomal epoxide hydrolase (mEH) for differences in drug response and cancer susceptibility has been investigated in various ethnic populations. LÄS MER

5. 14. Cytochrome P450 2C9, 2C19 and 2D6 genetic polymorphisms : evaluation of genotyping as a tool for individualised treatment

   Författare :Maria Gabriella Scordo; Karolinska Institutet; Karolinska Institutet; []
   Nyckelord :Drug metabolism; CYP2C9; CYP2C19; CYP2D6; genotyping; polymorphism; risperidone; warfarin; fluoxetine; phenytoin; extrapyramidal side-effects;

   Sammanfattning : Recent advances in the understanding of drug metabolism and the molecular biology of CYPs have generated great expectations regarding the use of pharmacogenetic testing as a tool to individualize drug treatment. The individual pharmacogenetic constitution might in principle predict the response to drugs, hormones and toxins. LÄS MER

7. 15. CYP2C19 catalyzed drug metabolism in different populations

   Författare :Karin Herrlin; Karolinska Institutet; Karolinska Institutet; []
   Nyckelord :CYP2C19; drug metabolism; cytochrome P450; mephenytoin; omeprazole; proguanil chloroguanide ; citalopram; debrisoquine; CYP2D6; gene duplication; pharmacogenetics;

   Sammanfattning : Metabolism catalyzed by the cytochrome P450 enzyme CYP2C19 varies between individuals, who can be either efficient (EM) or poor metabolizers (PM). In this thesis the metabolism of four different CYP2C19 substrates (citalopram, mephenytoin, omeprazole, and proguanil) was investigated in vivo in Africans (Ethiopians an Tanzanians) an in Swedish is Caucasians. LÄS MER